EVISTA Drug Patent Profile
✉ Email this page to a colleague
When do Evista patents expire, and when can generic versions of Evista launch?
Evista is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in EVISTA is raloxifene hydrochloride. There are seventeen drug master file entries for this compound. Seventeen suppliers are listed for this compound. Additional details are available on the raloxifene hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Evista
A generic version of EVISTA was approved as raloxifene hydrochloride by TEVA PHARMS USA on March 4th, 2014.
Summary for EVISTA
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 117 |
Clinical Trials: | 23 |
Patent Applications: | 3,488 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EVISTA |
What excipients (inactive ingredients) are in EVISTA? | EVISTA excipients list |
DailyMed Link: | EVISTA at DailyMed |
Recent Clinical Trials for EVISTA
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Massachusetts General Hospital | Phase 4 |
Shanghai Mental Health Center | Phase 4 |
National Cancer Institute (NCI) | Phase 2 |
Pharmacology for EVISTA
Drug Class | Estrogen Agonist/Antagonist |
Mechanism of Action | Selective Estrogen Receptor Modulators |
Anatomical Therapeutic Chemical (ATC) Classes for EVISTA
US Patents and Regulatory Information for EVISTA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for EVISTA
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
Lilly | EVISTA | raloxifene hydrochloride | TABLET;ORAL | 020815-001 | Dec 9, 1997 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for EVISTA
See the table below for patents covering EVISTA around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
United Kingdom | 9519028 | ⤷ Try a Trial | |
Canada | 2253858 | ⤷ Try a Trial | |
Norway | 974405 | ⤷ Try a Trial | |
Slovenia | 9500293 | SYNTHESIS OF 3-/4-(2-AMINOETHOXY)-BENZOYL/-2- ARYL-6-HYDROXYBENZO/B/ THYOPHENES | ⤷ Try a Trial |
Czechoslovakia | 227347 | METHOD OF PREPARING 6-HYDROXY-2-(4-HYDROXYPHENYL)-3-(4-(2-AMINOETHOXY) BENZOYL) BENZO (B)THIOPHENE | ⤷ Try a Trial |
Ireland | 820786 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for EVISTA
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0584952 | 980044 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: RALOXIFENE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER HET HYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/98/073/001 - EU/1/98/073/004, EU/1/98/074/001 - EU/1/98/074/004 19980805 EU/1/98/073/001 |
0584952 | SPC/GB98/048 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RALOXIFENE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/98/073/001 19980805; UK EU/1/98/073/002 19980805; UK EU/1/98/073/003 19980805; UK EU/1/98/073/004 19980805; UK EU/1/98/074/001 19980805; UK EU/1/98/074/002 19980805; UK EU/1/98/074/003 19980805; UK EU/1/98/074/004 19980805 |
0584952 | 1/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: RALOXIFEN ODER DESSEN PHARMEZEUTISCH ANNEHMBARE SALZE; REGISTRATION NO/DATE: EU/1/98/073/001- EU/1/98/073/004 19980805 |
0584952 | 99C0004 | Belgium | ⤷ Try a Trial | PRODUCT NAME: ESTRADIOL, HEMIHYDRATE, NORETHISTERONE, ACETATE; NAT. REGISTRATION NO/DATE: NL 23753 19981210; FIRST REGISTRATION: SE - 14 007 19980306 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |